<DOC>
	<DOCNO>NCT00003677</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness dolastatin 10 treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Dolastatin 10 Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity dolastatin 10 patient metastatic adenocarcinoma pancreas . II . Evaluate qualitative quantitative toxic effect therapy patient . III . Investigate clinical pharmacology treatment . OUTLINE : This open label , multicenter study . Patients receive dolastatin 10 IV bolus every 21 day . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month death . PROJECTED ACCRUAL : This study accrue 12-37 patient within 18.5 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Dolastatin 10</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma pancreas Bidimensionally measurable lesion sentinel lesion outside field prior radiation therapy No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina At least 6 month since prior myocardial infarction No uncontrolled hypertension Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent serious infection At least 5 year since prior malignancy except follow : Nonmelanoma skin cancer Carcinoma situ cervix No overt psychosis mental disability PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior chemotherapy metastatic disease At least 6 month since prior adjuvant chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 6 month since prior adjuvant chemoradiation disease At least 2 week since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 4 week since prior surgery recover No concurrent surgery Other : At least 4 week since prior investigational drug ( include analgesic antiemetic ) No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>